论文部分内容阅读
Newborn screening (NBS) is the largest population-based screening effort to pre-symptomatically detect treatable, inherited congenital disorders.Accurate laboratory screening of newborns using dried blood spot (DBS) specimens collected after birth ensures that affected babies receive early and appropriate medical intervention.NBS helps prevent developmental disabilities, severe illness and premature death.For more than 34 years, the Centers for Disease Control and Prevention (CDC) Newborn Screening Quality Assurance Program (NSQAP) has developed DBS reference materials and assisted laboratories with quality assurance (QA) programs through the use of DBS technology.The NSQAP is a uniquely comprehensive provider of QA services for NBS worldwide, preparing and distributing more than 850,000 DBS yearly to 88 US screening laboratories, more than 450 laboratories in 67 other countries,and 31 manufactures of diagnostic products.The CDC Newborn Screening Translation Research Initiative (NSTRI), collaboration with the CDC Foundation and its government, academic and corporate partners, anticipates the need for QA development as more disorders are considered for addition to NBS panels.Currently, NSTRI is working with NSQAP to support expansion of NBS for conditions such as severe combined immunodeficiency (SCID), and lysosomal storage disorders (LSD).